1 min read
Add as a preferred source on GoogleViridian Therapeutics Posts $24.7 Million in Lumvoa Net Product Revenue for Q3 2026
Total revenue was $25.752 million, and GAAP net loss per share was $0.81 on both basic and diluted bases.
Viridian Therapeutics generated $24.7 million in Lumvoa net product revenue during the third quarter of 2026, while total revenue reached $25.752 million for the period ended Sept. 30.
Net loss per common share was $0.81 on both basic and diluted bases. The results were released Nov. 4 and covered the three months ended Sept. 30, 2026.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.